Reported Saturday, iTeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High Non-small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
iTeos Therapeutics announced promising interim data from the GALAXIES Lung-201 Phase 2 study, sponsored by GSK, for the belrestotug and dostarlimab combination in treating high PD-L1 non-small cell lung cancer. The combination showed a high objective response rate and a favorable safety profile.
September 16, 2024 | 8:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK, as the sponsor of the GALAXIES Lung-201 study, benefits from the promising results of the belrestotug + dostarlimab combination, which may enhance its oncology portfolio.
GSK's role as the sponsor of the study positions it to benefit from the positive results, potentially enhancing its oncology portfolio and investor perception, leading to a positive short-term impact on its stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
iTeos Therapeutics' belrestotug + dostarlimab combination shows high efficacy in lung cancer treatment, with a significant ORR and a consistent safety profile, potentially boosting investor confidence.
The high ORR and consistent safety profile of the belrestotug + dostarlimab combination in the Phase 2 study are positive indicators for iTeos Therapeutics, suggesting potential success in the ongoing Phase 3 study. This could lead to increased investor confidence and a positive impact on ITOS stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90